

ASRS GLOBAL TRENDS IN RETINA

Africa/Middle East




Asia/Pacific



Singapore Society of Ophthalmology




Americas



Europe



2022




ASRS

GLOBAL
TRENDS


I N R E T I N A

Sunir J. Garg, MD, FACS, FASRS

2022




ASRS International Affairs



Preferences and Trends (PAT) Survey

42 societies accepted our invitation;
680 of their members answered the
2022 Global Trends in Retina Survey



GLOBAL TRENDS in Retina

Hahn P, Garg SJ, eds. *2022 Global Trends in Retina Survey*: Chicago, IL. American Society of Retina Specialists; 2022.

ASRS American Society of
Retina Specialists

GLOBAL TRENDS in Retina

International Affairs Committee Staff Liaison

Jennifer Carstens Schiller


ASRS PAT Survey Editors

Paul Hahn, MD, PhD, FASRS, *Editor*

Susan Raef, MSMC, *Managing Editor*

Research Consultant and Project Manager

Mindy Schneiderman, PhD



GLOBAL TRENDS in Retina

International Affairs Committee

Sunir J. Garg, MD, FACS, FASRS, *Chair*

J. Fernando Arevalo, MD, PhD, FACS, FASRS


Alay S. Banker, MD, FASRS

Ehab N. El-Rayes, MD, PhD, FASRS

Marta Figueroa, MD, PhD

Stratos V. Gotzaridis, MBBS, MD

Adnan Tufail, MBBS, MD, FRCOphth



GLOBAL TRENDS in Retina


International Liaison Leaders

J. Fernando Arevalo, MD, PhD, FACS, FASRS (Americas)

Alay S. Banker, MD, FASRS (Asia/Pacific)

Ehab N. El-Rayes, MD, PhD, FASRS (Africa/Middle East)

Adnan Tufail, MBBS, MD, FRCOphth (Europe)



Africa/Middle East



ARAB AFRICAN SOCIETY
of Retina Specialists

Arab African Society of Retina Specialists (AASRS)



ESO
EMIRATES SOCIETY OF
OPHTHALMOLOGY

Emirates Society of Ophthalmology



GRG
Gulf Retina Group

Gulf Retina Group



IRANIAN VITREORETINAL SOCIETY

Iranian Vitreoretinal Society



ISRAELI VITREORETINAL SOCIETY

Israel Vitreoretinal Society



JORDAN VITREORETINAL SOCIETY

The Jordan Vitreoretinal Society



NVRN
NIGERIAN VITREORETINAL SOCIETY

Nigerian Vitreoretinal Society




الجمعية السعودية لطب العيون
SAUDI OPHTHALMOLOGICAL SOCIETY

Saudi Ophthalmological Society



الجمعية السورية لطب العيون
SYRIAN OPHTHALMOLOGICAL SOCIETY

Syrian Ophthalmological Society



Asia/Pacific



Association of Vitreo-Retina Specialists of Sri Lanka



Australian and New Zealand Society of Retina Specialists



Indonesia Vitreoretinal Society



Japanese Retina and Vitreous Society



The Korean Retina Society



Malaysian Society of Ophthalmology



Singapore Society of Ophthalmology, Retina Section



Taiwan Retina Society




The Thai Retina Society



Vitreo Retina Society of India



The Vitreo Retina Society of The Philippines



Americas



Argentine Retina and Vitreous Society



Brazilian Retina and Vitreous Society



Canadian Retina Society



Colombian Retina and Vitreous Association



Mexican Retina Association



Pan-American Retina & Vitreous Society (PRVS)



Peruvian Society of Ophthalmology



Salvadoran Retina and Vitreous Association



Central American Retina and Vitreous Society (SCRV)



Uruguayan Association of Ophthalmology



Europe



Austrian Ophthalmological Society



British and Eire Association of Vitreoretinal Surgeons (BEAVRS)



Dutch Society of Vitreoretinal Surgery



Dutch Medical Retina Society



European Vitreoretinal Society

Club Francophone des Spécialistes de la Rétine



French Society of Retina Specialists



Greek Vitreo-Retinal Society (GVRS)



Italian Vitreoretinal Surgery Society



Rosengren Club—Swedish Vitreoretinal Society



Spanish Retina and Vitreous Society (SERV)



Turkish Ophthalmological Society




Ukrainian Alliance of Ophthalmologists




After a suboptimal response with Avastin for wet AMD, what is your next choice?


Avastin = bevacizumab, Genentech Inc Eylea = aflibercept, Regeneron Pharmaceuticals Inc Lucentis = ranibizumab, Genentech Inc




What anti-VEGF treatment regimen would you choose for a high myope with a new CNVM?




What is your usual approach to a chronic CSR (6 months), VA = 20/40, diffuse leak involving fovea?




How would you treat DME with an inadequate response to 3 monthly Lucentis or Eylea injections?




What percentage of your patients with CSDME on anti-VEGF therapy receive focal/grid laser?




How do you manage DR with massive peripheral nonperfusion on FA but no NV or DME?




Have you seen any retinovascular pathology shortly after COVID-19 and/or its vaccine?




Considering all indications, what is your most commonly used first-line anti-VEGF agent?




What is the most important factor in making your initial anti-VEGF treatment choice?




What does your current COVID-adapted IVI procedure include, in addition to masks?




What is your usual approach for a *phakic, inferior, macula-on* RD plus PVD with tear at 6:00?




Timing to operate on a symptomatic, ambulatory COVID-19 patient with < 1-day macula-off RD?




What is the typical size of your ILM peel when performing macular hole surgery?




How has the COVID-19 pandemic affected the economics of your practice?



Do you use social media platforms to market your practice, physicians, and/or services?



2022



ASRS

GLOBAL
TRENDS

I N R E T I N A

Thank You